Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LABT with free AI briefings, catalyst countdowns, and dilution alerts.

LABT · Lakewood-Amedex Biotherapeutics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$4.6M Cash on Hand
11.2mo Cash Runway
Follow LABT by email Get an email when LABT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LABT, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
10% Bisphosphocin Topical Gel Chronic Diabetic Foot Ulcers Phase 2 · NCT05276401 Terminated
10% Nu-3 gel Diabetic Foot Infection Phase 2 · NCT06020235 Not yet recruiting
5% Bisphosphocin Topical Gel Chronic Diabetic Foot Ulcers Phase 2 · NCT05276401 Terminated
5% Nu-3 gel Diabetic Foot Infection Phase 2 · NCT06020235 Not yet recruiting
Antibiotic Diabetic Foot Ulcers (DFUs) Phase 2 · NCT07565506 Recruiting
Bisphosphocin Nu-3 Diabetic Foot Infections Phase 1/2 · NCT02737722 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

LABT holds $4.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.2M/quarter from operations, an estimated runway of 11.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 53 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LABT files for a raise →

👥 Who Owns LABT

Insiders 13.5% Other 5%+ holders 54.7% Institutions (9 holders) 5.8% Public and other holders 26%
HolderTypeShares% of sharesAs of
HPW Investments Holding Ltd. 5%+ holder (13G) 3,435,501 38.39% 2026-04-23
WFI Equity, LLC 5%+ holder (13G) 1,259,684 14.07% 2026-05-13
Peter Ceccacci
Chief Financial Officer
Insider 468,148 5.23% 2026-04-17
Kelvin Cooper
Chief Executive Officer, Director
Insider 300,594 3.36% 2026-04-17
Thomas Balzer
Chief Medical Officer
Insider 255,322 2.85% 2026-04-17
LINDESFARNE LLC 5%+ holder (13G) 203,360 2.27% 2026-04-17
Leonard James DeRoma
Director
Insider 187,736 2.10% 2026-04-17

Share count 8,950,088 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full LABT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LABT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.